9 / 76
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 1, January/February 2017
AFRICA
7
myocardial infarction.
Am Heart J
2003;
145
: 147–153. PubMed PMID:
12514667.
6.
Barbagelata A, Granger CB, Topol EJ, Worley SJ, Kereiakes DJ, George
BS,
et al
. Frequency, significance and cost of recurrent ischemia after
thrombolytic therapy for acute myocardial infarction. TAMI Study
Group
. Am J Cardiol
1995;
76
: 1007–1013. PubMed PMID: 7484852.
7.
Uzunhasan I, Bader K, Okçun B, Hatemi AC, Mutlu H. Correlation of
the Tei index with left ventricular dilatation and mortality in patients
with acute myocardial infarction.
Int Heart J
2006;
47
: 331–342.
PubMed PMID: 16823239.
8.
Karatzis EN, Giannakopoulou AT, Papadakis JE, Karazachos AV,
Nearchou NS. Myocardial performance index (Tei index): Evaluating its
application to myocardial infarction.
Hellenic J Cardiol
2009;
50
: 60–65.
PubMed PMID: 19196622.
9.
Poulsen SH, Jensen SE, Nielsen JC, Møller JE, Egstrup K. Serial
changes and prognostic implications of a Doppler derived index of
combined left ventricular systolic and diastolic myocardial performance
in acute myocardial infarction.
Am J Cardiol
2000;
85
: 19–25. PubMed
PMID: 11078230.
10. Sahin DY, Gür M, Elbasan Z, Uysal OK, Özaltun B,
Ş
eker T,
et al
.
Relationship between myocardial performance index and severity of
coronary artery disease assessed with SYNTAX score in stable coronary
artery disease.
Echocardiography
2013;
30
(4): 385–391. PubMed PMID:
23228100.
11. Turfan M, Akyel A, Bolayir HA, Vatankulu MA, Aktürk M, Yetkin I,
et
al
. Correlation of the myocardial performance index with plasma B-type
natriureticpeptide levels in type 2 diabetes mellitus and impaired glucose
tolerance.
Kardiol Pol
2012;
70
(6): 556–562. PubMed PMID: 22718370.
12. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos
G,
et al
. The second Euro Heart Survey on acute coronary syndromes:
characteristics, treatment, and outcome of patients with ACS in Europe
and the Mediterranean Basin in 2004.
Eur Heart J
2006;
27
: 2285–2293.
PubMed PMID: 16908490.
Confidence Through Clinical
and Real World Experience
1-3
Millions of Patients Treated Across Multiple Indications
4
#1 NOAC prescribed by Cardiologists
*
References:
1.
Patel M.R., Mahaffey K.W., Garg J.
et al.
Rivaroxaban versus warfarin in non-valvular atrial fibrillation.
N Engl J Med
. 2011;365(10):883–91.
2.
Tamayo S., Peacock W.F., Patel M.R.,
et al.
Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.
Clin Cardiol
. 2015;38(2):63–8.
3.
Camm A.J., Amarenco P., Haas S.
et al.
XANTUS: A Real-World,
Prospective, Observational Study.
4.
Calculation based on IMS Health MIDAS, Database: Monthly Sales December 2015.
For fullprescribing information,refer to thepackage insertapprovedby theMedicinesRegulatoryAuthority (MCC). S4 XARELTO
®
10 (Film-coated tablets)
.Reg.No.:42/8.2/1046.Eachfilm-coated tabletcontainsrivaroxaban10mg.
PHARMACOLOGICALCLASSIFICATION:
A.8.2Anticoagulants.
INDICATION:
Prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery of the lower limbs. S4 XARELTO
®
15 and XARELTO
®
20 (Film-coated tablets). Reg. No.: XARELTO
®
15: 46/8.2/0111; XARELTO
®
20: 46/8.2/0112. Each film
coated tablet contains rivaroxaban 15 mg (XARELTO
®
15) or 20 mg (XARELTO
®
20).
PHARMACOLOGICAL CLASSIFICATION:
A.8.2 Anticoagulants.
INDICATIONS:
(1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2)
Treatment of deep vein thrombosis (DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep vein thrombosis (DVT).
HCR:
Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609. Tel: 011 921 5044 Fax: 011 921 5041.
L.ZA.MKT.GM.01.2016.1265
*Impact RX Data Oct - Dec 2015
NOAC: Non Vitamin K Oral Anticoagulant